Breast cancer remains the most diagnosed cancer in women, with an estimated 2.3 million new cases and 670,000 deaths worldwide in 2022. Early detection plays a crucial role in improving survival rates by allowing timely interventions that greatly increase the likelihood of successful treatment. Breast cancer can be classified into two main types: invasive breast cancer, which spreads beyond the breast tissue, and non-invasive or “in situ” breast cancer, where abnormal cells remain confined to the breast.
Access to traditional screening methods, such as mammography remains a challenge in many parts of the world, which can delay early detection. In response, Point-of-care (POC) testing is emerging as a valuable alternative. POC tests can detect specific biomarkers, such as CA 15-3 or HER2, that indicate the presence of breast cancer. These tests provide an accessible, fast, and reliable way to screen and monitor the disease, particularly in areas where advanced imaging technologies are limited.
Alix Joseph, Global Sales & Marketing Director Healthcare, offers his perspective on the impact of POC testing:
“Point-of-care testing provides concrete solutions for early detection of breast cancer in places where traditional methods are out of reach. For example, in rural or remote areas where mammography equipment is scarce or expensive, POC tests can be used to screen for key biomarkers such as HER2 or carcinoembryonic antigen (CEA). These tests can be performed quickly and with minimal equipment, allowing healthcare providers to make faster, more informed decisions. Another example is during chemotherapy treatment, where repeated testing is often required to monitor a patient’s response. POC tests allow clinicians to measure cancer markers such as CA 15-3 on the spot, helping them to adjust therapies in real time. This immediacy not only improves treatment outcomes but also reduces the burden on healthcare systems by reducing the need for more invasive procedures or follow-up visits.”
The World Health Organization (WHO) continues to emphasize early detection, timely diagnosis, and comprehensive breast cancer management in its strategy to reduce global mortality by 2024. In this context, the ability to provide accessible, cost-effective diagnostic tools, such as POC testing, will be vital to achieving these goals.
